James Quigley
Stock Analyst at Goldman Sachs
(0.49)
# 3,854
Out of 4,784 analysts
21
Total ratings
50%
Success rate
-25.02%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Initiates: Neutral | $65 | $55.82 | +16.45% | 1 | Mar 21, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Equal-Weight | $45 → $49 | $29.62 | +65.43% | 5 | Nov 6, 2024 | |
| NVS Novartis AG | Downgrades: Neutral | $119 → $121 | $112.57 | +7.49% | 1 | Sep 5, 2024 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $7.27 | +44.43% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $25.46 | +57.11% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.31 | +383.38% | 3 | Jun 23, 2023 |
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $55.82
Upside: +16.45%
Kymera Therapeutics
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $45 → $49
Current: $29.62
Upside: +65.43%
Novartis AG
Sep 5, 2024
Downgrades: Neutral
Price Target: $119 → $121
Current: $112.57
Upside: +7.49%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $7.27
Upside: +44.43%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $25.46
Upside: +57.11%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.31
Upside: +383.38%